secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001826667-25-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Life Sciences appoints David Patience as CFO; James Young resigns
--------------------------------------------------------------------------

- CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
- David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.
- Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.
- Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/0001826667-25-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000071/tlsi-20250523.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer